Treatment of ANCA-associated systemic small-vessel vasculitis

$48.00 plus tax (Refund Policy)

Download / Buy Article:


Jayne D. Treatment of ANCA-associated systemic small-vessel vasculitis. APMIS 2009; 117: 3–9.

Much has been learnt over the last 30 years to optimize the use of immunosuppressive and glucocorticoid therapies that has allowed the publication of treatment guidelines. However, major unmet needs remain in the treatment of ANCA-associated vasculitis (AAV) and include refractory disease, only partial efficacy and toxicity of current drugs and the need for long-term regimens. Newer therapies, including mycophenolate mofetil, leflunomide and rituximab, are providing a real opportunity for improved outcomes of AAV in the future. The development of therapy has been facilitated by international clinical research networks but delayed by the complexities of studying an uncommon, multi-system disease.

Keywords: ANCA; Treatment; international research; small-vessel vasculitis

Document Type: Research Article


Affiliations: Renal Unit, Addenbrooke's Hospital, Cambridge, UK

Publication date: June 1, 2009

Related content



Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more